Autologous and allogeneic haematopoietic cell transplantation in adult patients with Hodgkin lymphoma: recommendations from the EBMT Practice Harmonisation and Guidelines Committee and Lymphoma Working Party.

Date publication

juillet 2026

Journal

The Lancet. Haematology

Auteurs

Membres identifiés du Cancéropôle Est :
Pr ROSSI Cédric

Tous les auteurs :
Bazarbachi A, Advani R, Ahmed S, Carlo-Stella C, Castagna L, Eichenauer DA, El-Cheikh J, Hamadani M, Martinez C, Nicholson E, Peggs KS, Perales MA, Schmitz N, Specht L, Tanase AD, Onida F, Ruggeri A, Rossi C, Aljurf M, André M, Sánchez-Ortega I, Yakoub-Agha I, Sureda A

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/42392109

Résumé

The European Group for Blood and Bone Marrow transplantation Practice Harmonization and Guidelines Committee together with the Lymphoma Working Party convened 23 experts in Hodgkin lymphoma, transplantation, and radiation oncology, to develop consensus recommendations on the use of autologous and allogeneic haematopoietic cell transplantation (HCT) in relapsed or refractory Hodgkin lymphoma. Through a structured literature review and a 2-day workshop in Berlin, Germany, on Sept 29 and 30, 2025, the panel established guidance across major clinical decision points. The outcome of this review and workshop include the following recommendations. Salvage therapy should include brentuximab vedotin or checkpoint inhibitors, or both, with metabolic complete response preferred before autologous HCT. BEAM (carmustine, etoposide, cytarabine and melphalan) remains the most commonly used conditioning regimen, and autologous HCT continues to be the standard for chemosensitive relapse. Peri-transplantation radiotherapy could be considered for PET-positive or residual disease. Brentuximab vedotin consolidation is recommended for patients at high-risk. Allogeneic HCT is advised for eligible patients who relapse after autologous HCT, ideally with reduced intensity conditioning and post-transplantation cyclophosphamide as graft-versus-host disease prophylaxis. Routine maintenance after allogeneic HCT is not recommended; relapse management should be tailored and can involve donor lymphocyte infusion, brentuximab vedotin, checkpoint inhibitors, chemotherapy, radiotherapy, or clinical trial enrolment.

Mots clés

Humans, Hodgkin Disease, therapy, Hematopoietic Stem Cell Transplantation, methods, Transplantation, Autologous, Transplantation, Homologous, Adult, Transplantation Conditioning, methods, Antineoplastic Combined Chemotherapy Protocols, therapeutic use, Salvage Therapy, Brentuximab Vedotin, therapeutic use

Référence

Lancet Haematol. 2026 07;13(7):e484-e493